Tannervangsgaard7385

e current method is a stability-indicating assay method consisting of appropriate specificity, accuracy, precision and sensitivity. The developed method has a good potential to be adopted by the pharmaceutical industrial sector.The study was undertaken to identify the major mycotoxigenic fungi, aflatoxin and fumonisin levels in prepared poultry feeds in Ghana. Three hundred and fifty (350) prepared feed samples were randomly collected from 133 commercial poultry farms, 76 feed processors and eight (8) feed vendors in three major poultry producing regions of Ghana over two seasons. Fungi were isolated using the serial dilution method on potato dextrose agar and identified using standard methods of identification. Total aflatoxin and fumonisin levels were quantified using AgraStrip® Total Aflatoxin and Fumonisin Quantitative test Watex® from RomerLab, USA. Eight (8) different fungi were isolated from the feed samples with isolation frequency as follows Aspergillus flavus (47%), A. niger (24%), A. fumigatus (17%), A. oryzae (3%), A. tamarii (2%), Penicillium sp. (3%), Colletotrichum sp. (4%) and Rhizopus sp. (0.1%). Feed samples collected during the rainy season recorded higher mean colony counts (3.39 ± 0.29) than that of the dry season (1.10 ± 0.18). Total aflatoxin and fumonisin levels ranged from 0 to 118 ppb with a mean of 57.25 ± 2.55 ppb, and 0.28-15 ppm with a mean of 1.54 ± 0.12 ppm, respectively. The study revealed co-occurrence of aflatoxin and fumonisin in all the feed samples. Significant correlations (r = 0.298, r = 0.694) (p less then 0.05) were observed among the aflatoxin and fumonisin levels and the fungi isolated. selleck Seventy-four percent (74%) of all the feed samples exceeded the 15 ppb Ghana Standards Authority threshold, the EU regulatory limit of 20 ppb and the FAO/WHO recommended maximum permissible limit of 30 ppb for poultry feeds. Although fumonisin levels were less than the EU guidance values of 20 ppm for poultry feeds, 20% of the samples were higher than the FAO/WHO maximum tolerable daily intake limit of 2 ppm. Proper handling of prepared feeds and ingredients could prevent or minimize toxigenic fungi contamination and lower the likelihood of mycotoxin development in poultry feeds.Karyopherin beta 1 (Kpnβ1) is a major nuclear import receptor that mediates the import of cellular cargoes into the nucleus. Recently it has been shown that Kpnβ1 is highly expressed in several cancers, and its inhibition by siRNA induces apoptotic cancer cell death, while having little effect on non-cancer cells. This study investigated the effect of a novel small molecule, Inhibitor of Nuclear Import-60 (INI-60), on cancer cell biology, as well as nuclear import activities associated with Kpnβ1, and cancer progression in vivo using cervical and oesophageal cancer cell lines. INI-60 treatment resulted in the inhibition of cancer cell proliferation, colony formation, migration and invasion, and induced a G1/S cell cycle arrest, followed by cancer cell death via apoptosis. Non-cancer cells were minimally affected by INI-60 at concentrations that inhibited cancer cells. INI-60 treatment altered the localisation of Kpnβ1 and its cargoes, NFκB/p65, NFAT and AP-1, and the overexpression of Kpnβ1 reduced INI-60 cytotoxicity. INI-60 also inhibited KYSE 30 oesophageal cancer cell line growth in vivo. Taken together, these results show that INI-60 inhibits the nuclear import of Kpnβ1 cargoes and interferes with cancer cell biology. INI-60 presents as a potential therapeutic approach for cancers of different tissue origins and warrants further investigation as a novel anti-cancer agent.Melanoma, which originates from neural crest derived melanocytes, causes severe pain and even death to numerous patients. Previous studies reported that Notchless Homolog 1 (NLE1) plays an important role in cell proliferation, transcription and signal transduction. However, the clinical significance and biological behavior of NLE1 in melanoma remain a mystery. Thus, the role of NLE1 in melanoma was investigated in vitro and in vivo. The expression of NLE1 in melanoma was elevated and the expression level was positively correlated with lymphatic metastasis and tumor stage. In addition, NLE1 knockdown by shRNA specifically inhibited proliferation, enhanced the apoptotic sensitivity and hindered migration of melanoma cells in vitro. Mice xenograft model further showed that NLE1 knockdown could inhibit the tumor formation of melanoma in vivo. Additionally, the induction of apoptosis of melanoma cells by NLE1 knockdown required the participation of a series of apoptosis-related proteins. Besides, NLE1 can activate the PI3K/AKT signaling pathway. In summary, NLE1 was involved in the development and progression of melanoma, which may be a novel potential target for molecular therapy of melanoma.The epithalamic lateral habenula (LHb) regulates monoaminergic systems and contributes to the expression of both appetitive and aversive behaviours. Over the past years, the LHb has emerged as a vulnerable brain structure in mental illnesses including addiction. Behavioural and functional evidence in humans and rodents provide substantial support for a role of LHb in the negative affective symptoms emerging during withdrawal from addictive substances. Multiple forms of cellular and synaptic adaptations that take hold during drug withdrawal within the LHb are causally linked with the emergence of negative affective symptoms. These results indicate that targeting drug withdrawal-driven adaptations in the LHb may represent a potential strategy to normalize drug-related behavioural adaptations. In the current review we describe the mechanisms leading to functional alterations in the LHb, as well as the existing interventions used to counteract addictive behaviours. Finally, closing this loop we discuss and propose new avenues to potentially target the LHb in humans in light of the mechanistic understanding stemming from pre-clinical studies. Altogether, we provide an overview on how to leverage cellular-level understanding to envision clinically-relevant approaches for the treatment of specific aspects in drug addiction.